Patents by Inventor Matthias MEHLING

Matthias MEHLING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230093412
    Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
    Type: Application
    Filed: August 30, 2022
    Publication date: March 23, 2023
    Inventors: Jörg WISCHHUSEN, Markus Haake, Reinhard Dummer, Matthias Mehling, Tina SCHÄFER, Martina Selle
  • Patent number: 11464856
    Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 11, 2022
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT Würzburg
    Inventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling, Tina Schäfer, Martina Selle
  • Publication number: 20220242942
    Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
    Type: Application
    Filed: January 20, 2022
    Publication date: August 4, 2022
    Inventors: Jörg WISCHHUSEN, Markus Haake, Reinhard Dummer, Matthias Mehling
  • Patent number: 11262360
    Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 1, 2022
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling
  • Publication number: 20190160169
    Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 30, 2019
    Inventors: Jörg WISCHHUSEN, Markus HAAKE, Reinhard DUMMER, Matthias MEHLING, Tina SCHÄFER, Martina SELLE
  • Publication number: 20180292412
    Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 11, 2018
    Inventors: Jörg WISCHHUSEN, Markus HAAKE, Reinhard DUMMER, Matthias MEHLING